Fragment-based target screening as an empirical approach to prioritising targets: a case study on antibacterials.

Here, we describe a novel workflow combining informatic and experimental approaches to enable evidence-based prioritising of targets from large sets in parallel. High-throughput protein production and biophysical fragment screening is used to identify those targets that are tractable and ligandable. As proof of concept we have applied this to a set of antibacterial targets comprising 146 essential genes. Of these targets, 51 were selected and 38 delivered results that allowed us to rank them by ligandability. The data obtained against these derisked targets have enabled rapid progression into structurally enabled drug discovery projects, demonstrating the practical value of the fragment-based target screening workflow.

[1]  R. Lange,et al.  The targets of currently used antibacterial agents: lessons for drug discovery. , 2007, Current pharmaceutical design.

[2]  M. Koegl,et al.  Drugging an undruggable pocket on KRAS , 2019, Proceedings of the National Academy of Sciences.

[3]  Brian D. Marsden,et al.  High-throughput production of human proteins for crystallization: The SGC experience , 2010, Journal of structural biology.

[4]  David J Huggins,et al.  Quantitative metrics for drug-target ligandability. , 2018, Drug discovery today.

[5]  Roderick E. Hubbard,et al.  Current perspectives in fragment-based lead discovery (FBLD) , 2017, Essays in biochemistry.

[6]  Gaetano T Montelione,et al.  The high-throughput protein sample production platform of the Northeast Structural Genomics Consortium. , 2010, Journal of structural biology.

[7]  S. Geschwindner,et al.  Hot-Spotting with Thermal Scanning: A Ligand- and Structure-Independent Assessment of Target Ligandability. , 2017, Journal of medicinal chemistry.

[8]  Dean G. Brown,et al.  ESKAPEing the labyrinth of antibacterial discovery , 2015, Nature Reviews Drug Discovery.

[9]  Gang Yao,et al.  Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening , 2017, Nature Communications.

[10]  R. M. Owen,et al.  An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.

[11]  Stephen R. Johnson,et al.  Ligand and Target Discovery by Fragment-Based Screening in Human Cells , 2017, Cell.

[12]  Anthony M Giannetti,et al.  From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance. , 2011, Methods in enzymology.

[13]  P. Hajduk,et al.  Predicting protein druggability. , 2005, Drug discovery today.

[14]  M. Howarth,et al.  Site-specific biotinylation of purified proteins using BirA. , 2015, Methods in molecular biology.

[15]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[16]  Harren Jhoti,et al.  The 'rule of three' for fragment-based drug discovery: where are we now? , 2013, Nature Reviews Drug Discovery.

[17]  T. Clark,et al.  Genome-Wide Saturation Mutagenesis of Burkholderia pseudomallei K96243 Predicts Essential Genes and Novel Targets for Antimicrobial Development , 2014, mBio.

[18]  Rutger H A Folmer,et al.  Fragment screening to predict druggability (ligandability) and lead discovery success. , 2011, Drug discovery today.

[19]  R. Titball,et al.  Global Analysis of Genes Essential for Francisella tularensis Schu S4 Growth In Vitro and for Fitness during Competitive Infection of Fischer 344 Rats , 2019, Journal of bacteriology.

[20]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[21]  Orkun S. Soyer,et al.  An integrated computational-experimental approach reveals Yersinia pestis genes essential across a narrow or a broad range of environmental conditions , 2017, BMC Microbiology.